Regenerative medicine company CollPlant appointed Jonathan M.N. Rigby as chairman of the board of directors.
Four insights:
1. Mr. Rigby brings more than 28 years of experience in the pharmaceutical, biopharmaceutical, medical device and drug delivery industries to CollPlant.
2. Previously, Mr. Rigby was president and CEO of SteadyMed, a specialty pharmaceutical company that United Therapeutics bought in August 2018.
3. Along with his new role at CollPlant, Mr. Rigby will continue to serve as president and CEO of SteadyMed, a United Therapeutics corporation.
4. CollPlant focuses on 3D bioprinting of tissues and organs, medical aesthetics and the development and commercialization of tissue repair products for orthobiologics.